公开(公告)号：US20080287521A1

公开(公告)日：2008-11-20

申请号：US12172503

申请日：2008-07-14

申请人： Stephen Robert Byrn ,  David Andrew Coates ,  Karen Sue Gushurst ,  Joseph Francis Krzyzaniak ,  Zheng Jane Li ,  Henry Grant Morrison, II ,  Aeri Park ,  Petinka Ivanova Vlahova

发明人： Stephen Robert Byrn ,  David Andrew Coates ,  Karen Sue Gushurst ,  Joseph Francis Krzyzaniak ,  Zheng Jane Li ,  Henry Grant Morrison, II ,  Aeri Park ,  Petinka Ivanova Vlahova

IPC分类号： A61K31/40

CPC分类号： A61K31/401 ,  C07D207/34

摘要： Novel crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt designated Form V, Form VI, Form VII, Form VIII, Form IX, Form X, Form XI, Form XII, Form XIII, Form XIV, Form XV, Form XVI, Form XVII, Form XVIII, and Form XIX are characterized by their X-ray powder diffraction, solid-state NMR, and/or Raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, and Alzheimer's disease.

摘要翻译： [R-（R *，R *）] - 2-（4-氟苯基） - ，δ-二羟基-5-（1-甲基乙基）-3-苯基-4 - [（苯基氨基）羰基] 表示VI，形式VII，形式VIII，形式IX，形式X，表格XI，表格XII，表格XIII，表格XIV，表格XV，表格XVI，表格 XVII，XVIII型和XIX型的特征在于它们的X射线粉末衍射，固态NMR和/或拉曼光谱，以及其制备方法及其药物组合物，其可用作试剂 用于治疗高脂血症，高胆固醇血症，骨质疏松症和阿尔茨海默病。

公开(公告)号：US07144915B2

公开(公告)日：2006-12-05

申请号：US10456046

申请日：2003-06-06

申请人： Stephen Robert Byrn ,  David Andrew Coates ,  Karen Sue Gushurst ,  Joseph Francis Krzyzaniak ,  Zheng Jane Li ,  Henry Grant Morrison, II ,  Aeri Park ,  Petinka Ivanova Vlahova

发明人： Stephen Robert Byrn ,  David Andrew Coates ,  Karen Sue Gushurst ,  Joseph Francis Krzyzaniak ,  Zheng Jane Li ,  Henry Grant Morrison, II ,  Aeri Park ,  Petinka Ivanova Vlahova

IPC分类号： A61K31/40 ,  A61P3/06 ,  A61P19/10 ,  A61P25/28 ,  C07D207/34

CPC分类号： A61K31/401 ,  C07D207/34

摘要： Novel crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt designated Form V, Form VI, Form VII, Form VIII, Form IX, Form X, Form XI, Form XII, Form XIII, Form XIV, Form XV, Form XVI, Form XVII, Form XVIII, and Form XIX are characterized by their X-ray powder diffraction, solid-state NMR, and/or Raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, and Alzheimer's disease.

摘要翻译： [R-（R *，R *）] - 2-（4-氟苯基） - ，δ-二羟基-5-（1-甲基乙基）-3-苯基-4 - [（苯基氨基）羰基] 表示VI，形式VII，形式VIII，形式IX，形式X，表格XI，表格XII，表格XIII，表格XIV，表格XV，表格XVI，表格 XVII，XVIII型和XIX型的特征在于它们的X射线粉末衍射，固态NMR和/或拉曼光谱，以及其制备方法及其药物组合物，其可用作试剂 用于治疗高脂血症，高胆固醇血症，骨质疏松症和阿尔茨海默病。

公开(公告)号：US06605729B1

公开(公告)日：2003-08-12

申请号：US10184669

申请日：2002-06-28

申请人： Stephen Robert Byrn ,  David Andrew Coates ,  Karen Sue Gushurst ,  Joseph Francis Krzyzaniak ,  Zheng Jane Li ,  Henry Grant Morrison, II ,  Aeri Park ,  Petinka Ivanova Vlahova

发明人： Stephen Robert Byrn ,  David Andrew Coates ,  Karen Sue Gushurst ,  Joseph Francis Krzyzaniak ,  Zheng Jane Li ,  Henry Grant Morrison, II ,  Aeri Park ,  Petinka Ivanova Vlahova

IPC分类号： C07D20734

CPC分类号： A61K31/401 ,  C07D207/34

摘要： Novel crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-&bgr;,&dgr;-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt designated Form V, Form VI, Form VII, Form VIII, Form IX, Form X, Form XI, Form XII, Form XIII, Form XIV, Form XV, Form XVI, Form XVII, Form XVIII, and Form XIX are characterized by their X-ray powder diffraction, solid-state NMR, and/or Raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, and Alzheimer's disease.

摘要翻译： [R-（R *，R *）] - 2-（4-氟苯基） - ，δ-二羟基-5-（1-甲基乙基）-3-苯基-4 - [（苯基氨基）羰基] 表示VI，形式VII，形式VIII，形式IX，形式X，表格XI，表格XII，表格XIII，表格XIV，表格XV，表格XVI，表格 XVII，XVIII型和XIX型的特征在于它们的X射线粉末衍射，固态NMR和/或拉曼光谱，以及其制备方法及其药物组合物，其可用作试剂 用于治疗高脂血症，高胆固醇血症，骨质疏松症和阿尔茨海默病

公开(公告)号：US20080214651A1

公开(公告)日：2008-09-04

申请号：US11977459

申请日：2007-10-25

申请人： Stephen Robert Byrn ,  David Andrew Coates ,  Karen Sue Gushurst ,  Joseph Francis Krzyzaniak ,  Zheng Jane Li ,  Henry Grant Morrison ,  Aeri Park ,  Petinka Ivanova Vlahova

发明人： Stephen Robert Byrn ,  David Andrew Coates ,  Karen Sue Gushurst ,  Joseph Francis Krzyzaniak ,  Zheng Jane Li ,  Henry Grant Morrison ,  Aeri Park ,  Petinka Ivanova Vlahova

IPC分类号： A61K31/401 ,  A61P25/28

CPC分类号： A61K31/401 ,  C07D207/34

摘要： Novel crystalline forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt designated Form V, Form VI, Form VII, Form VIII, Form IX, Form X, Form XI, Form XII, Form XIII, Form XIV, Form XV, Form XVI, Form XVII, Form XVIII, and Form XIX are characterized by their X-ray powder diffraction, solid-state NMR, and/or Raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, and Alzheimer's disease.

摘要翻译： [R-（R *，R *）] - 2-（4-氟苯基） - ，δ-二羟基-5-（1-甲基乙基）-3-苯基-4 - [（苯基氨基）羰基] 表示VI，形式VII，形式VIII，形式IX，形式X，表格XI，表格XII，表格XIII，表格XIV，表格XV，表格XVI，表格 XVII，XVIII型和XIX型的特征在于它们的X射线粉末衍射，固态NMR和/或拉曼光谱，以及其制备方法及其药物组合物，其可用作试剂 用于治疗高脂血症，高胆固醇血症，骨质疏松症和阿尔茨海默病。